The University of Chicago Header Logo
Last Name


Michael H. Davidson to Molecular Targeted Therapy

This is a "connection" page, showing publications Michael H. Davidson has written about Molecular Targeted Therapy.

Connection Strength
  1. Benes LB, Brandt DJ, Brandt EJ, Davidson MH. How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention. Curr Cardiol Rep. 2018 10 17; 20(12):138.
    View in: PubMed
    Score: 0.609
  2. Davidson MH. Beta-2 Agonism: A Potential Therapeutic Target for Dyslipidemia. EBioMedicine. 2015 Apr; 2(4):284.
    View in: PubMed
    Score: 0.474
  3. Davidson MH. Therapies targeting exogenous cholesterol uptake: new insights and controversies. Curr Atheroscler Rep. 2011 Feb; 13(1):95-100.
    View in: PubMed
    Score: 0.357
  4. Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, Hudak JE, Lakins JN, Wijekoon AC, Cassereau L, Rubashkin MG, Magbanua MJ, Thorn KS, Davidson MW, Rugo HS, Park JW, Hammer DA, Giannone G, Bertozzi CR, Weaver VM. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature. 2014 Jul 17; 511(7509):319-25.
    View in: PubMed
    Score: 0.028
  5. Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, D'Agostino RB, Davidson MH, Davidson WS, Heinecke JW, Karas RH, Kontush A, Krauss RM, Miller M, Rader DJ. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013 Sep-Oct; 7(5):484-525.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.